The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial

Neoadjuvant chemotherapy (NaCT) and neoadjuvant endocrine therapy (NET) can reduce pre-operative tumour burden in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer. This prospective translational study assessed the ability of a 12-gene molecular score (MS; EndoPredict ®) to predict response to NaCT or NET within the ABCSG-34 trial.

Source: European Journal of Cancer - June 1, 2020 Category: Cancer & Oncology Authors: Peter C. Dubsky, Christian F. Singer, Daniel Egle, Viktor Wette, Edgar Petru, Marija Balic, Angelika Pichler, Richard Greil, Andreas L. Petzer, Zsuzsanna Bago-Horvath, Christian Fesl, Stephanie M. Meek, Ralf Kronenwett, Margaretha Rudas, Michael Gnant, Ma Tags: Original Research Source Type: research